What Is Akathisia?
Akathisia is a movement disorder characterized by an intense, distressing sensation of inner restlessness and an uncontrollable urge to move. The name comes from the Greek word meaning “inability to sit,” which describes the core experience reported by patients who suffer from this condition.
People with akathisia often feel compelled to pace, rock, shift their weight, or fidget constantly. The sensation is not simply physical restlessness — it includes a deeply uncomfortable internal agitation that patients frequently describe as one of the worst experiences of their lives.
Akathisia can be caused by a wide range of psychiatric medications, including antipsychotics, antidepressants, and anti-nausea drugs. It can also occur during withdrawal from benzodiazepines, SSRIs, and other medications that affect the central nervous system.
The condition is frequently misdiagnosed as anxiety, agitation, or worsening of the original psychiatric condition. This misdiagnosis can lead to increased medication doses, which may actually worsen the akathisia rather than treat it.
Akathisia has been associated with increased risk of self-harm and suicidal ideation, particularly when the condition goes unrecognized. Accurate identification and appropriate treatment are critical for patient safety.
What Causes Akathisia?
The most common cause of akathisia is exposure to dopamine-blocking medications, particularly antipsychotic drugs. First-generation antipsychotics like haloperidol carry the highest risk, but second-generation antipsychotics such as quetiapine (Seroquel), olanzapine (Zyprexa), and aripiprazole (Abilify) can also trigger the condition.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are another well-documented cause. Medications like sertraline (Zoloft), escitalopram (Lexapro), and venlafaxine (Effexor) can induce akathisia, particularly during initiation or dose changes.
Benzodiazepine withdrawal is a significant and often overlooked cause of akathisia. When benzodiazepines are discontinued too rapidly, the resulting GABA-A receptor dysfunction can produce severe akathisia as part of Benzodiazepine-Induced Neurological Dysfunction (BIND).
Anti-nausea medications such as metoclopramide (Reglan) and prochlorperazine (Compazine) block dopamine receptors and carry akathisia risk similar to antipsychotic medications. These drugs are sometimes prescribed without adequate warning about this potential side effect.
The underlying mechanism involves disruption of dopaminergic pathways in the brain, particularly in the basal ganglia. When dopamine transmission is blocked or altered, the resulting neurochemical imbalance produces the characteristic sensation of restlessness and the compulsion to move.
Recognizing Akathisia Symptoms
The hallmark symptom of akathisia is a subjective sense of inner restlessness that patients describe as deeply uncomfortable and impossible to ignore. This internal sensation distinguishes akathisia from simple physical restlessness or anxiety, though the conditions can look similar from the outside.
Observable motor symptoms include pacing back and forth, rocking while seated or standing, crossing and uncrossing the legs repeatedly, and an inability to remain in one position. Some patients march in place, shift their weight continuously, or swing their legs while sitting.
The psychological component of akathisia can include intense anxiety, irritability, emotional distress, and a sense of impending doom. Patients may feel unable to relax regardless of their environment, and the distress often worsens with attempts to remain still.
Sleep disruption is common because the restlessness does not stop at night. Patients may find it impossible to lie still long enough to fall asleep, or they may wake frequently due to the compulsion to move. This sleep deprivation compounds the overall distress of the condition.
Akathisia exists on a spectrum of severity. Mild cases involve noticeable restlessness that the patient can partially suppress, while severe cases produce constant, uncontrollable movement and overwhelming psychological distress that significantly impairs daily functioning.
Akathisia From Benzodiazepine Withdrawal
Akathisia that develops during or after benzodiazepine withdrawal is one of the most distressing manifestations of BIND. The sudden loss of GABA-A receptor enhancement that benzodiazepines provide can push the nervous system into a hyperexcitable state that produces severe restlessness.
Rapid benzodiazepine discontinuation or overly aggressive tapering schedules increase the risk of withdrawal-induced akathisia significantly. Patients who are detoxed quickly in addiction treatment facilities are particularly vulnerable, as these programs often do not recognize the distinction between physical dependence and addiction.
The Ashton Manual’s recommendation for slow, gradual tapering exists in part to prevent severe withdrawal complications like akathisia. A properly managed taper using the diazepam crossover protocol gives the GABA-A receptors time to begin recovering at each dose level.
Withdrawal-induced akathisia can persist for months after the benzodiazepine has been completely discontinued. This protracted form of akathisia is part of the broader protracted withdrawal syndrome that some patients experience regardless of how carefully they tapered.
Patients experiencing akathisia during a benzodiazepine taper should communicate this to their physician immediately. The taper pace may need to be slowed, paused, or adjusted to allow the nervous system more time to stabilize before further dose reductions.
How Akathisia Is Misdiagnosed
Akathisia is one of the most frequently misdiagnosed conditions in psychiatric medicine. Because its symptoms overlap with anxiety, agitation, and psychomotor activation, clinicians who are not specifically looking for akathisia often attribute the symptoms to worsening of the patient’s underlying condition.
This misdiagnosis can have serious consequences. If a patient’s akathisia is interpreted as worsening anxiety, the clinician may increase the dose of the medication causing the akathisia or add another medication, which can intensify the problem.
Patients who report akathisia symptoms are sometimes told that they are simply anxious and need to try harder to relax. This dismissal of a legitimate neurological adverse effect has been described as medical gaslighting by patient advocacy organizations, including the Benzodiazepine Information Coalition.
The distinction between akathisia and anxiety can be identified through careful clinical assessment. Akathisia involves a specific compulsion to move that is experienced as involuntary, whereas anxiety-driven restlessness is typically accompanied by worried thoughts and can be partially relieved by reassurance or relaxation techniques.
Healthcare providers who prescribe medications with akathisia risk should monitor patients specifically for this side effect, particularly during the first few weeks of treatment or after dose changes. Early recognition allows for prompt intervention before the condition becomes severe.
Treatment Approaches for Akathisia
The primary treatment for medication-induced akathisia is reducing the dose of or discontinuing the causative medication. For akathisia caused by antipsychotic or antidepressant medications, a physician experienced in deprescribing can develop a gradual tapering plan to safely reduce the offending drug.
Beta-blockers, particularly propranolol, have shown effectiveness in reducing akathisia symptoms in some patients. Propranolol works by blocking peripheral beta-adrenergic receptors, which may help counteract the autonomic activation component of akathisia.
Benzodiazepines have been used to treat akathisia in acute settings, though this approach creates its own risks of dependence. For patients who developed akathisia from benzodiazepine withdrawal, this option is generally not appropriate as it would reverse the tapering progress.
Mirtazapine, a medication with serotonin receptor blocking properties, has shown benefit for some patients with SSRI-induced akathisia. The choice of treatment depends on the suspected cause, the severity of symptoms, and the patient’s overall medication profile.
For withdrawal-induced akathisia, time and nervous system recovery are the most reliable treatments. The condition typically improves as the brain’s receptor systems gradually return to their pre-medication baseline, though this recovery can take months.
Preventing Akathisia During Medication Changes
Slow, gradual dose changes when starting, adjusting, or stopping psychiatric medications are the most effective strategy for preventing akathisia. The Maudsley Deprescribing Guidelines recommend hyperbolic tapering schedules that reduce the risk of neurological side effects during medication discontinuation.
Patients who have experienced akathisia from one medication are at increased risk of developing it again from related medications. This history should be documented and considered whenever medication changes are being discussed.
For benzodiazepine tapering, the Ashton Manual’s diazepam crossover protocol reduces akathisia risk by providing stable blood levels and enabling very gradual dose reductions. Compound pharmacy formulations allow for precise dosing at the small increments needed to minimize withdrawal complications.
Physicians should establish regular check-ins during any medication change to monitor for early signs of akathisia. Catching the condition early, when symptoms are mild, allows for dosage adjustments before the akathisia becomes severe and debilitating.
Patient education about akathisia symptoms empowers individuals to recognize the condition and report it promptly. Many patients do not know that akathisia exists as a distinct medical condition and may suffer in silence, believing their symptoms are simply anxiety or a personal failing.
Getting Help for Akathisia and Medication Tapering
Patients experiencing akathisia from psychiatric medications or benzodiazepine withdrawal benefit from working with a physician who specifically understands this condition. General practitioners and psychiatrists do not always receive training on akathisia recognition and management.
A deprescribing specialist can evaluate the patient’s medication history, identify the likely cause of the akathisia, and develop a tapering plan that minimizes the risk of further neurological complications. This specialized approach differs significantly from standard psychiatric practice.
Mark Leeds, D.O. provides psychiatric medication deprescribing and benzodiazepine tapering services via telemedicine. Dr. Leeds uses the Ashton Manual crossover protocol for benzodiazepine tapering and applies the Maudsley Deprescribing Guidelines for SSRI and antipsychotic medication reductions.
As a member of the Benzodiazepine Information Coalition’s medical advisory board, Dr. Leeds is specifically attuned to withdrawal-related conditions like akathisia and BIND. Each patient receives an individualized treatment plan with weekly appointments for close monitoring.
Patients who suspect they are experiencing akathisia, whether from a current medication or from withdrawal, can schedule a telemedicine consultation with Dr. Leeds to discuss their symptoms and treatment options.
